Avid Bioservices Inc (CDMO)

[freethemice]

Mojojojo, I hadn't really given this much thought before. But, you definitely have a point. The problem arises
because of the existence of a drug that has a realistic chance to work on many cancers. A pan-cancer treatment.
When these guidelines were adopted nothing like that was on the horizon. Avastin was the first biologic drug that
worked on several different cancers, but it hasn't turned out to have the wide use that was first thought.
However, there are many chemo drugs that are used on many different cancers. Docetaxel for example.
I think the difference here is the potential uses with bavituximab are much bigger. So is it possible to
keep the uses of bavituximab under control? Of course cancer patients don't care about that, nor would a BP
that had a license for NSCLC, if it wasn't against the FDA rules, they would be happy to sell as much as possible.
There is one thing that might help here. Bavituximab is only made by Avid, the sole supplier. Would it be possible
for Avid/Peregrine to control the flow of bavi to only NSCLC patients? I know that any doctor is suppose to be free
to prescribe any approved drug for what uses he/she deems it useful for, but maybe some new rules need to be made.
If only oncologists can prescribe it, and they would have to certify that it is only for use with NSCLC in writing, maybe
that would work. As it is now the doctors don't care because it is the BP that suffers for selling the drug for off-label use.
I know the doctors will all be against this so it probably won't work, but I don't know what else would work. This will
become a more visible problem if by the end of the year there is good data from the pancreatic and liver cancer trials.